
THE PROBLEM
Depression is a leading cause of disability and suffering worldwide. 300 million people suffer from depression globally, costing the world economy USD 1 trillion in lost productivity.
Depression costs the Australian economy AUD 6 billion in direct and indirect costs..
1 in 3 patients recovering from their first depression episode is likely to relapse, turning depression into a chronic disease.
Prolonged sympathetic nervous arousal or fight or flight activity in the body is a leading risk factor for depression relapse.
Relapse turns depression into a chronic disease

Philia Labs’ solution for relapse prevention

What it is:
- User-friendly platform to enable earlier interventions by the clinician
- Patient-friendly wearable
- Clinically validated algorithms to quantify stress in real-time
- Reporting system for clinician
Who it is for:
- Patients undergoing depression treatment and at risk of relapse
- Psychiatrist prescribes wearable + data monitoring program

A new standard for measuring sympathetic arousal in the body
TEAM

DILPREET
BUXI
PhD
CEO &
Co-founder

ALEXANDER SENIOR
BSc, BEng (Hons)
Head of Product & Co-founder

DAVID
LESTER
PhD
Head of Strategy & Medical Affairs

MELANIE J. WHITE
BSc (Hons), Wellness coaching NBHWC
Head of Growth

KATI SARAFRAZI
PhD
Biomedical Data Scientist

NICHOLAS MELLOR
BSc, BEng
Algorithm Engineer

MADHURA MAHAMUNKAR
MSc
Applications Engineer

AUDREY
TAN
BSc
IT Engineer

RITA KOUCHAYAN
MOL
User Experience
Our Advisors

PAUL FITZGERALD
MBBS, MPM, PhD
Strategic Clinical Advisor

VINAYAK SMITH
MBBS
Strategic Clinical Advisor

BEN STEER
MBA
Strategic Advisor
OUR PARTNERS
Careers